The first combination treatment for patients with hyperuricemia associated with gout has received . Specifically, the new medication is indicated for patients who haven鈥檛 achieved target serum uric acid levels with allopurinol alone.
Marketed as Duzallo, the new oral medication combines allopurinol, a xanthine oxidase inhibitor, with lesinurad, a selective uric acid reabsorption inhibitor that was . Together they address both underlying causes of hyperuricemia鈥攐verproduction and inefficient excretion of serum uric acid. The medication will be available in combinations of 200 mg of lesinurad plus 300 mg of allopurinol and 200 mg of each drug.